Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-finding study of Osteodex in castration-resistant prostate cancer with skeletal metastases
2015-005666-37Phase 2Completed
- Sponsor
- DexTech Medical
- Start
- Dec 2015
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of OsteoDex in castration-resistant prostate cancer (CRPC), sponsored by DexTech Medical. Started Dec 2015; status: completed.
02
Drugs
OsteoDex
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2015-005666-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005666-37.